<h4>Background</h4>Gliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represent alone or in combination a promising treatment option for patients with type II diabetes mellitus. Here, SLC5A2 is linked to type 2 diabetes mellitus.